CRISPR Gene Repair for RDEB Keratinocytes Using AAV6 Donor Templates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene editing technologies for recessive dystrophic Epidermolysis Bullosa (RDEB) are inefficient and laborious, particularly in achieving high frequencies of homologous recombination (HR)-based gene correction in primary keratinocytes, which are crucial for treating this severe skin disorder.
Innovation Solution
A method using a combination of AAV6-delivered donor templates with the CRISPR/Cas9 system, specifically designed recombinant donor templates lacking introns, to induce HR-based gene correction in primary keratinocytes, achieving up to 40% corrected transcripts and restoring collagen VII expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional gene editing methods (TALENs, ZFNs, Meganucleases) are used to correct COL7A1 mutations, then gene correction can be achieved, but the correction efficiency is low (2-4% HDR correction) and the process is laborious
Solution Approach 1:
The patent changes the molecular parameters of the editing system by using CRISPR/Cas9 with specifically designed sgRNAs targeting intron-exon boundaries, combined with optimized donor templates lacking introns. This parameter change in the editing mechanism achieves up to 40% HDR correction efficiency in primary keratinocytes, representing a 10-fold improvement over traditional methods while reducing procedural complexity
Solution Approach 2:
The patent extracts and removes the intronic sequences from the donor template, creating a streamlined donor construct that contains only the essential coding sequences and regulatory elements. This extraction of non-essential intronic DNA simplifies the donor template design and enhances HDR efficiency by providing a cleaner template for homology-directed repair
2Manufacturing precision
If homologous recombination-based correction is used to precisely correct mutations, then precise gene correction can be achieved, but the frequency of correction is low compared to NHEJ pathway
Solution Approach 1:
The patent performs preliminary design and optimization of donor templates that are specifically tailored for HDR efficiency. The donor templates are constructed with optimized homology arms, appropriate promoter sequences, and exon-specific designs that prepare the system in advance for high-efficiency HDR. This preliminary optimization enables precise correction to occur at high frequency rather than low frequency
Solution Approach 2:
The patent introduces AAV6 vectors as an intermediary delivery system that efficiently transports the donor template into primary keratinocytes. The AAV6 vector serves as a mediator that facilitates the transfer of the corrected COL7A1 sequence into the target cells, significantly enhancing the frequency of HDR events while maintaining precision through the specific design of the donor template
3Productivity
If CRISPR/Cas9 system is used to induce double-strand breaks, then gene editing can be achieved, but the desired HDR-based correction frequency is not achieved in primary keratinocytes
Solution Approach 1:
The patent applies local quality optimization by designing sgRNAs that specifically target intron-exon boundaries rather than random genomic locations. This localized targeting strategy, combined with donor templates that match the specific mutation location, creates optimal conditions for HDR at the precise site needed. The local optimization of guide RNA design and donor template matching ensures both high frequency and high reliability of correction
Solution Approach 2:
The patent creates a composite gene editing system that combines CRISPR/Cas9 nucleases with AAV6-delivered donor templates. This composite approach integrates two different components (the editing machinery and the delivery vehicle) to achieve synergistic effects. The combination provides both the capability to induce breaks and the means to efficiently deliver repair templates, resulting in reliable and frequent HDR correction
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a stable and efficient gene correction in a significant portion of primary keratinocytes, enabling the restoration of dermo-epidermal adhesion and potential clinical translation for treating RDEB.
Implementation Method 1
DNA double-strand breaks will be repaired by homologous recombination (HR) in the presence of a donor sequence for Epidermolysis Bullosa gene repair
Data Source
AI summary
The present invention relates to the treatment of Epidermolysis Bullosa, particularly the recessive dystrophic subtype (RDEB), using the Clustered-Regularly Interspaced Short Palindromic Repeats (CRISPR) system. This technology offers the possibility to design a single guide RNA (sgRNA) which is incorporated into a CRISPR-associated protein (Cas9) to recognize and induce DNA double-strand breaks at a specific target location. DNA double-strand breaks will be repaired by homologous recombination (HR) in the presence of a donor sequence for Epidermolysis Bullosa gene repair. In the context of Epidermolysis Bullosa, this allows to repair the mutation/s causing the disease.